Intraobserver and interobserver reproducibility of WHO and Gleason histologic grading systems in prostatic adenocarcinomas

Özdamar, Şükrü Oğuz; Sarıkaya, Şaban; Yıldız, Levent; Ati̇lla, Mustafa Kemal; Kandemır, Bedrı; Yıldız, Sevda

doi:10.1007/bf02550141

Cited by 56 publications

(42 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is likely to result from intraobserver and interobserver variability in Gleason grading and sampling error in taking the biopsy. Ozdamar et al (1996) showed that grading error was greatest with welldifferentiated (Gleason scores 2 -4) tumours. In these cases, the accuracy was only 15% with needle biopsy (Ozdamar et al, 1996).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype

et al. 2008

View full text Add to dashboard Cite

There is a high and rising prevalence of prostate cancer (PRCA) within the male population of the United Kingdom. Although the relative risk of PRCA is higher in male BRCA2 and BRCA1 mutation carriers, the histological characteristics of this malignancy in these groups have not been clearly defined. We present the histopathological findings in the first UK series of BRCA1 and BRCA2 mutation carriers with PRCA. The archived histopathological tissue sections of 20 BRCA1/2 mutation carriers with PRCA were collected from histopathology laboratories in England, Ireland and Scotland. The cases were matched to a control group by age, stage and serum PSA level of PRCA cases diagnosed in the general population. Following histopathological evaluation and re-grading according to current conventional criteria, Gleason scores of PRCA developed by BRCA1/2 mutation carriers were identified to be significantly higher (Gleason scores 8, 9 or 10, P ¼ 0.012) than those in the control group. Since BRCA1/2 mutation carrier status is associated with more aggressive disease, it is a prognostic factor for PRCA outcome. Targeting screening to this population may detect disease at an earlier clinical stage which may therefore be beneficial. British Journal of Cancer (2008) Prostate cancer (PRCA) is the most commonly diagnosed malignancy in men in the United Kingdom. It is thought to be composed of aggressive and indolent varieties. Indolent PRCA may exist for many years without causing symptoms or shortening life expectancy. Aggressive PRCA may cause symptoms difficult to palliate with conventional treatments and is likely to shorten life expectancy. Distinguishing which men are at risk of which types of disease could have far-reaching consequences not only in the treatment and follow-up of patients but also in the surveillance of groups at risk of aggressive PRCA.The morphology of breast cancer found in female BRCA1 and BRCA2 germline mutation carriers has been studied extensively. The histopathological features of breast tumours from patients with BRCA1 and BRCA2 mutations differ from each other and from sporadic breast cancers . BRCA1 and BRCA2 breast cancers are of higher grade (Lakhani, 2001). BRCA1-associated tumours are more likely to be oestrogen, progesterone receptor and Her2 receptor negative, express TP53 protein, and demonstrate medullary/atypical medullary morphology. Lakhani (2001) predicts that a woman diagnosed with high-grade, oestrogen receptor-negative breast cancer before the age of 30 years has a 40-45% chance of harbouring a BRCA1 mutation, compared with a 4-5% chance if these parameters are not met (Lakhani, 2001). Many of the features identified in breast cancer in women who are BRCA1 mutation carriers are associated with a poor prognosis. If similar data were available for men with PRCA who are carriers of these mutations, weighing up the options for radical treatment or active surveillance could be simplified with this added information.Despite studies on the incidence of PRCA in male BRCA1 and BRCA2 mutation...

show abstract

Section: Discussionmentioning

confidence: 99%

“…Ozdamar et al (1996) showed that grading error was greatest with welldifferentiated (Gleason scores 2 -4) tumours. In these cases, the accuracy was only 15% with needle biopsy (Ozdamar et al, 1996). Of patients with Gleason scores 5 -7 on needle biopsy, 97% were graded correctly.…”

Section: Discussionmentioning

confidence: 99%

Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Reproducibility studies can be categorized as intra-observer and interobserver; for investigations of intra-observer agreement of Gleason grades, exact agreement was reported in 43-78% of cases [49,50], and agreement within plus or minus one Gleason score unit was reported in 72-87% of cases. Gleason wrote that he duplicated exactly his previous histological scores about half the time.…”

Section: Intra-observer and Interobserver Variabilitymentioning

confidence: 99%

Gleason grading of prostate cancer in needle biopsies or radical prostatectomy specimens: contemporary approach, current clinical significance and sources of pathology discrepancies

et al. 2005

View full text Add to dashboard Cite

The Gleason grading system is a powerful tool to prognosticate and aid in the treatment of men with prostate cancer. The needle biopsy Gleason score correlates with virtually all other pathological variables, including tumour volume and margin status in radical prostatectomy specimens, serum prostate‐specific antigen levels and many molecular markers. The Gleason score assigned to the tumour at radical prostatectomy is the most powerful predictor of progression after radical prostatectomy. However, there are significant deficiencies in the practice of this grading system. Not only are there problems among practising pathologists but also a relative lack of interobserver reproducibility among experts.

show abstract

“…The gold standard technique for diagnosing and characterising prostate cancer is currently histological examination of prostate biopsy cores. The subjective nature of this technique means that it is associated with considerable interand intraobserver variation in reporting (Ozdamar et al, 1996;Allsbrook et al, 2001). As the therapeutic options available to treat prostate cancer increase, so does the importance of accurate characterization of the tumour.…”

mentioning

confidence: 99%

The use of Raman spectroscopy to differentiate between different prostatic adenocarcinoma cell lines

et al. 2005

View full text Add to dashboard Cite

Raman spectroscopy (RS) is an optical technique that provides an objective method of pathological diagnosis based on the molecular composition of tissue. Studies have shown that the technique can accurately identify and grade prostatic adenocarcinoma (CaP) in vitro. This study aimed to determine whether RS was able to differentiate between CaP cell lines of varying degrees of biological aggressiveness. Raman spectra were measured from two well-differentiated, androgen-sensitive cell lines (LNCaP and PCa 2b) and two poorly differentiated, androgen-insensitive cell lines (DU145 and PC 3). Principal component analysis was used to study the molecular differences that exist between cell lines and, in conjunction with linear discriminant analysis, was applied to 200 spectra to construct a diagnostic algorithm capable of differentiating between the different cell lines. The algorithm was able to identify the cell line of each individual cell with an overall sensitivity of 98% and a specificity of 99%. The results further demonstrate the ability of RS to differentiate between CaP samples of varying biological aggressiveness. RS shows promise for application in the diagnosis and grading of CaP in clinical practise as well as providing molecular information on CaP samples in a research setting.

show abstract

Intraobserver and interobserver reproducibility of WHO and Gleason histologic grading systems in prostatic adenocarcinomas

Cited by 56 publications

References 10 publications

Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype

Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype

Gleason grading of prostate cancer in needle biopsies or radical prostatectomy specimens: contemporary approach, current clinical significance and sources of pathology discrepancies

The use of Raman spectroscopy to differentiate between different prostatic adenocarcinoma cell lines

Contact Info

Product

Resources

About